Clinical Observation Of Shenqi Zhuyu Decoction In Treating Reduced Ejection Fraction Of Heart Failure(Qi Deficiency And Blood Stasis Type)after Coronary Stent Implantation

Objective: To assess the clinical efficacy and safety of Shenqi Zhuyu Decoction in the treatment of heart failure with reduced ejection fraction(Qi deficiency and blood stasis type)after coronary heart disease stenting,and to explore the treatment plan of integrated traditional Chinese and Western Medicine on heart failure with reduced ejection fraction(HFr EF)after coronary heart disease stenting,so as to develop the advantages of traditional Chinese medicine.Methods: A total of 70 eligible patients from the Cardiology Department and the Cardiac Department of the Sichuan Provincial Hospital of Traditional Chinese Medicine were collected from March 2018 to August 2019.Random number table method was used to divide the test group and control group,with 35 cases in each group.Among them,the control group was given a standard western medicine regimen,and the experimental group was added with the Chinese medicine Shenqi Zhuyu Decoction on this basis.The course of treatment was 4 weeks,and the follow-up period was 3 months.Observe the changes in related efficacy and safety indicators before and after treatment.Finally,SPSS 24.0 software was used to analyze the experimental data.Results:(1)Both treatment options can reduce scores in TCM syndromes,improve New York's cardiac function classification,reduce heart failure Minnesota quality of life scores and NT-pro BNP levels,increase 6-minute walking distance and 24-hour urine output.(P <0.05).(2)The experimental group was superior to the control group in reducing TCM syndrome scores and heart failure Minnesota quality of life scores,increasing 6-minute walking distance,and improving cardiac function in New York.The differences were statistically significant(P <0.05).(3)There was no significant difference in NT-pro BNP,left ventricular ejection fraction,24-hour urine output,and the occasional systolic blood pressure between the two groups after treatment(P>0.05).(4)Compared with the control group,the experimental group can more effectively reduce the re-hospitalization rate of patients admitted for 3 months,and the difference is statistically significant(P <0.05).(5)There were no serious adverse reactions throughout the test,and the laboratory safety indicators did not change significantly compared with the previous ones.There was no significant difference between groups and within groups(P > 0.05).Conclusion: Shenqi Zhuyu Decoction can significantly improve the clinical symptoms?increase activity tolerance?improve New York heart function classification ?improve quality of life and reduce the 3-month readmission rate of patients with reduced ejection fraction heart failure(Qi deficiency and blood stasis type)after coronary heart disease stenting.And the drug is safe and feasible,and can be promoted for clinical use.